Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $9.75.

ACRS has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday.

Institutional Investors Weigh In On Aclaris Therapeutics

Institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its position in shares of Aclaris Therapeutics by 409.0% in the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 45,864 shares in the last quarter. HighTower Advisors LLC increased its holdings in Aclaris Therapeutics by 20.2% in the 1st quarter. HighTower Advisors LLC now owns 316,064 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 53,116 shares in the last quarter. OMERS ADMINISTRATION Corp raised its position in Aclaris Therapeutics by 223.3% in the first quarter. OMERS ADMINISTRATION Corp now owns 175,900 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 121,500 shares during the period. State of Wyoming acquired a new position in shares of Aclaris Therapeutics during the first quarter worth about $72,000. Finally, Palo Alto Investors LP boosted its position in shares of Aclaris Therapeutics by 36.2% in the first quarter. Palo Alto Investors LP now owns 776,028 shares of the biotechnology company’s stock worth $1,187,000 after buying an additional 206,196 shares during the period. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Performance

Shares of ACRS stock opened at $2.88 on Monday. The firm has a market capitalization of $312.05 million, a price-to-earnings ratio of -2.09 and a beta of 0.41. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $3.47. The company has a 50 day moving average price of $2.76 and a 200 day moving average price of $2.11.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. The company had revenue of $3.30 million for the quarter, compared to analyst estimates of $1.59 million. As a group, equities analysts forecast that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.